TWI367209B - - Google Patents

Info

Publication number
TWI367209B
TWI367209B TW094130939A TW94130939A TWI367209B TW I367209 B TWI367209 B TW I367209B TW 094130939 A TW094130939 A TW 094130939A TW 94130939 A TW94130939 A TW 94130939A TW I367209 B TWI367209 B TW I367209B
Authority
TW
Taiwan
Application number
TW094130939A
Other languages
Chinese (zh)
Other versions
TW200619212A (en
Inventor
Yoshihito Tanaka
Shuzo Takeda
Hidemitsu Higashi
Mamoru Matsuura
Fujio Kobayashi
Maiko Hamada
Minoru Tanaka
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of TW200619212A publication Critical patent/TW200619212A/zh
Application granted granted Critical
Publication of TWI367209B publication Critical patent/TWI367209B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW094130939A 2004-09-08 2005-09-08 Morpholine derivatives TW200619212A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004261655 2004-09-08

Publications (2)

Publication Number Publication Date
TW200619212A TW200619212A (en) 2006-06-16
TWI367209B true TWI367209B (US06903085-20050607-C00131.png) 2012-07-01

Family

ID=36036551

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094130939A TW200619212A (en) 2004-09-08 2005-09-08 Morpholine derivatives

Country Status (13)

Country Link
US (1) US7935700B2 (US06903085-20050607-C00131.png)
EP (1) EP1801108B9 (US06903085-20050607-C00131.png)
JP (1) JP4970946B2 (US06903085-20050607-C00131.png)
KR (1) KR101011848B1 (US06903085-20050607-C00131.png)
CN (1) CN101014580B (US06903085-20050607-C00131.png)
CA (1) CA2579207C (US06903085-20050607-C00131.png)
DK (1) DK1801108T3 (US06903085-20050607-C00131.png)
ES (1) ES2396419T3 (US06903085-20050607-C00131.png)
IN (1) IN2014CN03493A (US06903085-20050607-C00131.png)
PL (1) PL1801108T3 (US06903085-20050607-C00131.png)
PT (1) PT1801108E (US06903085-20050607-C00131.png)
TW (1) TW200619212A (US06903085-20050607-C00131.png)
WO (1) WO2006028284A1 (US06903085-20050607-C00131.png)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE398616T1 (de) * 2005-02-04 2008-07-15 Ctg Pharma S R L Neue 4-aminochinolinderivate als antimalariamittel
ES2401482T3 (es) 2005-05-10 2013-04-22 Incyte Corporation Moduladores de la indolamina 2,3-dioxigenasa y métodos de uso de los mismos
EP1971583B1 (en) 2005-12-20 2015-03-25 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008007691A1 (fr) 2006-07-11 2008-01-17 Mitsubishi Tanabe Pharma Corporation Sels de composé de morpholine
CL2007002650A1 (es) * 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
ES2444574T3 (es) * 2006-09-19 2014-02-25 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa
US20080146624A1 (en) * 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
WO2008058178A1 (en) * 2006-11-08 2008-05-15 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP2143714B1 (en) 2007-04-04 2013-06-05 Kowa Company, Ltd. Tetrahydroisoquinoline compound
RS53688B9 (sr) 2008-07-08 2020-01-31 Incyte Holdings Corp 1,2,5-oksadiazoli kao inhibitori indoleamin 2,3-dioksigenaze
WO2015012332A1 (ja) * 2013-07-24 2015-01-29 田辺三菱製薬株式会社 眼科疾患治療剤
US9321755B2 (en) 2013-11-08 2016-04-26 Incyte Corporation Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
WO2020203822A1 (ja) * 2019-03-29 2020-10-08 千寿製薬株式会社 血管新生を伴う網膜疾患の治療又は予防のための併用医薬
US20220280487A1 (en) * 2019-08-26 2022-09-08 Stichting Vumc Inhibition of mycobacterial type vii secretion

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870074A (en) 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
JPS63264467A (ja) * 1986-04-30 1988-11-01 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体
JPH03148276A (ja) * 1989-11-01 1991-06-25 Yoshitomi Pharmaceut Ind Ltd 光学活性なピリドンカルボン酸化合物
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
JP2000516210A (ja) 1996-07-12 2000-12-05 ロイコサイト,インコーポレーテッド ケモカインレセプターアンタゴニストとその使用方法
AU3633997A (en) 1996-07-29 1998-02-20 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1999055330A1 (en) 1998-04-27 1999-11-04 Smithkline Beecham Corporation Ccr-3 receptor antagonists
WO1999055324A1 (en) 1998-04-27 1999-11-04 Smithkline Beecham Corporation Ccr-3 receptor antagonists
WO2000031033A1 (en) 1998-11-20 2000-06-02 F. Hoffmann-La Roche Ag Piperidine ccr-3 receptor antagonists
US6492364B1 (en) 1998-12-04 2002-12-10 Toray Industries, Inc. Triazolo and derivatives as chemokine inhibitors
WO2000053600A1 (fr) 1999-03-11 2000-09-14 Banyu Pharmaceutical Co., Ltd. Derives piperidiniques
PL350904A1 (en) 1999-03-26 2003-02-10 Astrazeneca Ab Novel compounds
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
WO2002018335A1 (fr) 2000-08-28 2002-03-07 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amine cyclique
CN1678594A (zh) 2000-09-29 2005-10-05 葛兰素集团有限公司 用于治疗炎性疾病的吗啉-乙酰胺衍生物
CN1478084A (zh) 2000-09-29 2004-02-25 用于治疗炎性疾病的化合物
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
EP1389616B1 (en) 2001-04-27 2011-07-27 Mitsubishi Tanabe Pharma Corporation 3,4-Dihalobenzylpiperidine derivatives and their medical use
GB0207439D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0208158D0 (en) 2002-03-28 2002-05-22 Glaxo Group Ltd Novel compounds
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
GB0207443D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207445D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0212355D0 (en) 2002-05-29 2002-07-10 Glaxo Group Ltd Novel compounds
GB0212357D0 (en) 2002-05-29 2002-07-10 Glaxo Group Ltd Novel compounds
WO2004004731A1 (en) 2002-07-02 2004-01-15 F. Hoffmann-La Roche Ag 2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix

Also Published As

Publication number Publication date
CN101014580B (zh) 2011-05-04
EP1801108B9 (en) 2013-11-20
EP1801108A1 (en) 2007-06-27
PT1801108E (pt) 2012-12-03
CA2579207A1 (en) 2006-03-16
KR20070099528A (ko) 2007-10-09
JP4970946B2 (ja) 2012-07-11
WO2006028284A1 (ja) 2006-03-16
CN101014580A (zh) 2007-08-08
CA2579207C (en) 2011-10-18
DK1801108T3 (da) 2013-02-18
JPWO2006028284A1 (ja) 2008-05-08
TW200619212A (en) 2006-06-16
PL1801108T3 (pl) 2013-04-30
KR101011848B1 (ko) 2011-02-01
ES2396419T3 (es) 2013-02-21
US20070265257A1 (en) 2007-11-15
US7935700B2 (en) 2011-05-03
IN2014CN03493A (US06903085-20050607-C00131.png) 2015-07-03
EP1801108B1 (en) 2012-11-14
EP1801108A4 (en) 2010-10-13

Similar Documents

Publication Publication Date Title
BE2022C549I2 (US06903085-20050607-C00131.png)
BE2020C513I2 (US06903085-20050607-C00131.png)
BE2020C517I2 (US06903085-20050607-C00131.png)
BE2019C540I2 (US06903085-20050607-C00131.png)
BE2019C548I2 (US06903085-20050607-C00131.png)
BE2018C045I2 (US06903085-20050607-C00131.png)
BE2017C027I2 (US06903085-20050607-C00131.png)
BE2017C023I2 (US06903085-20050607-C00131.png)
BE2017C002I2 (US06903085-20050607-C00131.png)
BE2016C067I2 (US06903085-20050607-C00131.png)
BE2016C014I2 (US06903085-20050607-C00131.png)
BE2015C041I2 (US06903085-20050607-C00131.png)
BE2015C038I2 (US06903085-20050607-C00131.png)
BE2015C066I2 (US06903085-20050607-C00131.png)
BE2015C014I2 (US06903085-20050607-C00131.png)
BE2014C071I2 (US06903085-20050607-C00131.png)
BE2014C064I2 (US06903085-20050607-C00131.png)
BE2014C063I2 (US06903085-20050607-C00131.png)
BE2019C535I2 (US06903085-20050607-C00131.png)
BE2014C010I2 (US06903085-20050607-C00131.png)
BE2013C071I2 (US06903085-20050607-C00131.png)
BE2015C065I2 (US06903085-20050607-C00131.png)
BR122015024347A2 (US06903085-20050607-C00131.png)
BRPI0508002A (US06903085-20050607-C00131.png)
BE2016C042I2 (US06903085-20050607-C00131.png)

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees